|
ddn Cancer Research News Exclusive
Collaring colorectal cancer
Mount Sinai researchers discover that soy-derived genistein can
impact a signaling pathway responsible for driving growth of colorectal cancer
(Pictured above, Randall Holcombe, M.D.)
Genistein’s
effect on colorectal cancer primarily consists of its inhibition of the Wnt
pathway, a signaling pathway found in roughly 85 percent of colon and rectal
cancers. With a low side effect profile, as well as some demonstrated, if not
definitive, evidence of its preventive abilities, genistein represents an
“exciting area of research,” according to Randall Holcombe, M.D., of Mount
Sinai.
|
|
|
|
|
TCGA Research Network releases a detailed classification of the genomic alterations and mutations seen in acute myeloid leukemia, offering new insight into the cancer's pathogenesis as well as potential new drug targets
|
|
The companies will make their respective vaccines available at prices that represent a nearly 95-percent discount to normal commercial prices
|
|
Mount Sinai researchers discover that soy-derived genistein can impact a signaling pathway responsible for driving growth of colorectal cancer
|
|
Concert Pharmaceuticals announces a strategic collaboration with Celgene Corp. aimed at developing deuterium-modified compounds against oncology and inflammation targets
|
|
The team-up of the two companies will focus on the discovery and development of novel antibody-drug conjugates against oncology targets, using Ambrx's protein medicinal chemistry technology
|
|
First five projects named to pilot Florida Translational Research Program
|
|
OGT granted prostate cancer biomarker license by the ICR
|
|
Six-way partnership attempts synergy in inhibiting protein kinases to develop novel drugs
|
|
|
Survey highlights link between companion diagnostics and
future of cancer research
ddn readers say
molecular diagnostics are essential part of oncology drug development
Click here to download a PDF of the results of our latest ddn Market Research survey, as reported in ddn's May 2013 issue
by Kelsey Kaustinen
|
|
Angelina Jolie made waves when she revealed that she'd undergone a preventive double mastectomy after genetic testing revealed she had a mutated BRCA1 gene that gave her a high risk of breast and ovarian cancer. Jolie, who lost her mother to cancer, said she shared her story so other women would be aware of their options.
|
|
|
|
|
